Evidence map›Paper›PMID 28405192›Full record

ArticleFrontiers in microbiology2017

Induction of Osteopontin by Dengue Virus-3 Infection in THP-1 Cells: Inhibition of the Synthesis by Brefelamide and Its Derivative.

Dyshelly N Pascapurnama, Hannah K M Labayo, Isolde Dapat, Divya D Nagarajegowda, Jingge Zhao, Jing Zhang, Osamu Yamada, Haruhisa Kikuchi, Shinichi Egawa, Yoshiteru Oshima and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Dyshelly N PascapurnamaDivision of International Cooperation for Disaster Medicine, International Research Institute of Disaster Science, Tohoku University Sendai, Japan.
Hannah K M LabayoDivision of Emerging Infectious Diseases, Graduate School of Medicine, Tohoku University Sendai, Japan.
Isolde DapatDivision of Disaster-related Infectious Diseases, International Research Institute of Disaster Science, Tohoku University Sendai, Japan.
Divya D NagarajegowdaDivision of Emerging Infectious Diseases, Graduate School of Medicine, Tohoku University Sendai, Japan.
Jingge ZhaoDivision of Disaster-related Infectious Diseases, International Research Institute of Disaster Science, Tohoku University Sendai, Japan.
Jing ZhangResearch and Development Center, FUSO Pharmaceutical Industries, Ltd Osaka, Japan.
Osamu YamadaResearch and Development Center, FUSO Pharmaceutical Industries, Ltd Osaka, Japan.
Haruhisa KikuchiLaboratory of Natural Product Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University Sendai, Japan.
Shinichi EgawaDivision of International Cooperation for Disaster Medicine, International Research Institute of Disaster Science, Tohoku University Sendai, Japan.
Yoshiteru OshimaLaboratory of Natural Product Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University Sendai, Japan.
Haorile Chagan-YasutanDivision of Emerging Infectious Diseases, Graduate School of Medicine, Tohoku UniversitySendai, Japan; Division of Disaster-related Infectious Diseases, International Research Institute of Disaster Science, Tohoku UniversitySendai, Japan.
Toshio HattoriDivision of Emerging Infectious Diseases, Graduate School of Medicine, Tohoku UniversitySendai, Japan; Division of Disaster-related Infectious Diseases, International Research Institute of Disaster Science, Tohoku UniversitySendai, Japan; Graduate School of Health Science and Social Welfare, Kibi International UniversityTakahashi, Japan.
Tohoku University · JPFuso Pharmaceutical Industries (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteopontin (OPN) is a multifunctional matricellular protein produced by a broad range of cells including osteoclasts, macrophages, T cells, endothelial cells, and vascular smooth muscle cells. OPN modulates various physiological and pathological events such as inflammation, wound healing, and bone formation and remodeling. Dengue virus (DENV) infection causes an increase in plasma OPN levels, which is correlated with the severity of symptoms and coagulation abnormalities. DENV infection also induces

Indexed as

293T cellbrefelamidedengue virus-3osteopontinTHP-1 cell

Identifiers

PMID28405192
PMCPMC5370276
OpenAlexW2597455181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.